The molecular mechanisms and therapeutic potential of microRNA-7 in cancer

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 3, 2015, Pages 415-426

  Gu, Dian Na ^a   Huang, Qian ^a   Tian, Ling ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cancer cell signaling; MicroRNA; MicroRNA 7; MicroRNA based therapeutics; Post transcriptional regulation

Indexed keywords

CYCLIN E; CYCLIN E1; EPIDERMAL GROWTH FACTOR RECEPTOR; FOCAL ADHESION KINASE; INTEGRIN; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 7; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; P21 ACTIVATED KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME; PROTEASOME ACTIVATOR 28 SUBUNIT GAMMA; PROTEIN BCL 2; PROTEIN CDC42; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; SOMATOMEDIN C; TRANSCRIPTION FACTOR YY1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; MIRN7 MICRORNA, HUMAN;

ANTINEOPLASTIC ACTIVITY; BIOGENESIS; CANCER CELL; CARCINOGENESIS; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; MOLECULAR BIOLOGY; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ANIMAL; GENETICS; NEOPLASMS; PATHOLOGY; RNA INTERFERENCE;

ANIMALS; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84923084512     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.988708     Document Type: Review

References (103)

1. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 2014;15:509-24
2. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010;9:775-89
3. Ruan K, Fang X, Ouyang G. MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 2009;285:116-26
4. Lagos-Quintana M, Rauhut R, Lendeckel W, et al. Identification of novel genes coding for small expressed RNAs. Science 2001;294:853-8
5. Kefas B, Godlewski J, Comeau L, et al. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 2008;68:3566-72
6. Chen YJ, Chien PH, Chen WS, et al. Hepatitis B virus-encoded X protein downregulates EGFR expression via inducing MicroRNA-7 in hepatocellular carcinoma cells. Evid Based Complement Alternat Med 2013;2013:682380
7. Xu L, Wen Z, Zhou Y, et al. MicroRNA-7-regulated TLR9 signaling-enhanced growth and metastatic potential of human lung cancer cells by altering the phosphoinositide-3-kinase, regulatory subunit 3/Akt pathway. Mol Biol Cell 2013;24:42-55
8. Kong X, Li G, Yuan Y, et al. MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression. PLoS One 2012;7:e41523
9. Zhao X, Dou W, He L, et al. MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. Oncogene 2013;32:1363-72
10. Luo J, Cai Q, Wang W, et al. A microRNA-7 binding site polymorphism in HOXB5 leads to differential gene expression in bladder cancer. PLoS One 2012;7:e40127
11. Kalinowski FC, Giles KM, Candy PA, et al. Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7. PLoS One 2012;7:e47067
12. Zhang N, Li X, Wu CW, et al. microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis. Oncogene 2013;32:5078-88
13. Yu Z, Ni L, Chen D, et al. Identification of miR-7 as an oncogene in renal cell carcinoma. J Mol Histol 2013;44:669-77
14. Giles KM, Brown RA, Epis MR, et al. miRNA-7-5p inhibits melanoma cell migration and invasion. Biochem Biophys Res Commun 2013;430:706-10
15. Liu S, Zhang P, Chen Z, et al. MicroRNA-7 downregulates XIAP expression to suppress cell growth and promote apoptosis in cervical cancer cells. FEBS Lett 2013;587:2247-53
16. Jiang L, Liu X, Chen Z, et al. MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochem J 2010;432:199-205
17. Kalinowski FC, Brown RA, Ganda C, et al. MicroRNA-7: a tumor suppressor miRNA with therapeutic potential. Int J Biochem Cell Biol 2014;54:312-17
18. Duex JE, Comeau L, Sorkin A, et al. Usp18 regulates epidermal growth factor (EGF) receptor expression and cancer cell survival via microRNA-7. J Biol Chem 2011;286:25377-86
19. Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. Nature 2013;495:384-8
20. Rai K, Takigawa N, Ito S, et al. Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol Cancer Ther 2011;10:1720-7
21. Lee KM, Choi EJ, Kim IA. microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. Radiother Oncol 2011;101:171-6
22. Tazawa H, Yano S, Yoshida R, et al. Genetically engineered oncolytic adenovirus induces autophagic cell death through an E2F1-microRNA-7-epidermal growth factor receptor axis. Int J Cancer 2012;131:2939-50
23. MiRBase. miRNA gene family: mir-7 (140 sequences). Available from: http://www.mirbase.org/cgi-bin/mirna-summary.pl?fam=MIPF0000022
24. NCBI database, Gene. Available from: http://www.ncbi.nlm.nih.gov/gene/? term=hsa-mir-7
25. Landgraf P, Rusu M, Sheridan R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007;129:1401-14
26. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 2005;6:376-85
27. Fang Y, Xue JL, Shen Q, et al. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology 2012;55:1852-62
28. Karsy M, Arslan E, Moy F. Current progress on understanding microRNAs in glioblastoma multiforme. Genes Cancer 2012;3:3-15
29. Xiong S, Zheng Y, Jiang P, et al. PA28gamma emerges as a novel functional target of tumour suppressor microRNA-7 in non-small-cell lung cancer. Br J Cancer 2014;110:353-62
30. Webster RJ, Giles KM, Price KJ, et al. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 2009;284:5731-41
31. Chou YT, Lin HH, Lien YC, et al. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res 2010;70:8822-31
32. Foekens JA, Sieuwerts AM, Smid M, et al. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci USA 2008;105:13021-6
33. Rao Q, Shen Q, Zhou H, et al. Aberrant microRNA expression in human cervical carcinomas. Med Oncol 2012;29:1242-8
34. Cheng AM, Byrom MW, Shelton J, et al. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 2005;33:1290-7
35. Carrio M, Arderiu G, Myers C, et al. Homeobox D10 induces phenotypic reversion of breast tumor cells in a three-dimensional culture model. Cancer Res 2005;65:7177-85
36. Reddy SD, Ohshiro K, Rayala SK, et al. MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res 2008;68:8195-200
37. O'Donnell KA, Wentzel EA, Zeller KI, et al. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005;435:839-43
38. McInnes N, Sadlon TJ, Brown CY, et al. FOXP3 and FOXP3-regulated microRNAs suppress SATB1 in breast cancer cells. Oncogene 2012;31:1045-54
39. Wu H, Sun S, Tu K, et al. A splicing-independent function of SF2/ASF in microRNA processing. Mol Cell 2010;38:67-77
40. Lebedeva S, Jens M, Theil K, et al. Transcriptome-wide analysis of regulatory interactions of the RNA-binding protein HuR. Mol Cell 2011;43:340-52
41. Li YJ, Wang CH, Zhou Y, et al. TLR9 signaling repressed tumor suppressor miR-7 expression through up-regulation of HuR in human lung cancer cells. Cancer Cell Int 2013;13:90
42. Choudhury NR, de Lima Alves F, de Andres-Aguayo L, et al. Tissue-specific control of brain-enriched miR-7 biogenesis. Genes Dev 2013;27:24-38
43. Wang Y, Vogel G, Yu Z, et al. The QKI-5 and QKI-6 RNA binding proteins regulate the expression of microRNA 7 in glial cells. Mol Cell Biol 2013;33:1233-43
44. Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 2013;495:333-8
45. Hansen TB, Kjems J, Damgaard CK. Circular RNA and miR-7 in cancer. Cancer Res 2013;73:5609-12
46. Yano S, Kondo K, Yamaguchi M, et al. Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res 2003;23:3639-50
47. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001;98:10983-5
48. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res 1998;74:49-139
49. Liu Z, Liu Y, Li L, et al. MiR-7-5p is frequently downregulated in glioblastoma microvasculature and inhibits vascular endothelial cell proliferation by targeting RAF1. Tumour Biol 2014;35(10):10177-84
50. Wang W, Dai LX, Zhang S, et al. Regulation of epidermal growth factor receptor signaling by plasmid-based microRNA-7 inhibits human malignant gliomas growth and metastasis in vivo. Neoplasma 2013;60:274-83
51. Khan KH, Yap TA, Yan L, et al. Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J Cancer 2013;32:253-65
52. Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008;135:1972-83.1983 e1-11
53. Werner H, Bruchim I. The insulin-like growth factor-I receptor as an oncogene. Arch Physiol Biochem 2009;115:58-71
54. Annunziata M, Granata R, Ghigo E. The IGF system. Acta Diabetol 2011;48:1-9
55. Yousif NG. Fibronectin promotes migration and invasion of ovarian cancer cells through up-regulation of FAK-PI3K/Akt pathway. Cell Biol Int 2014;38:85-91
56. Macagno JP, Diaz Vera J, Yu Y, et al. FAK acts as a suppressor of RTK-MAP kinase signalling in Drosophila melanogaster epithelia and human cancer cells. PLoS Genet 2014;10:e1004262
57. Graham K, Moran-Jones K, Sansom OJ, et al. FAK deletion promotes p53-mediated induction of p21, DNA-damage responses and radio-resistance in advanced squamous cancer cells. PLoS One 2011;6:e27806
58. Zhao X, Guan JL. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv Drug Deliv Rev 2011;63:610-15
59. Golubovskaya VM. Targeting FAK in human cancer: from finding to first clinical trials. Front Biosci (Landmark Ed) 2014;19:687-706
60. Wu DG, Wang YY, Fan LG, et al. MicroRNA-7 regulates glioblastoma cell invasion via targeting focal adhesion kinase expression. Chin Med J (Engl) 2011;124:2616-21
61. Ye DZ, Field J. PAK signaling in cancer. Cell Logist 2012;2:105-16
62. Saydam O, Senol O, Wurdinger T, et al. miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways. Cancer Res 2011;71:852-61
63. Arias-Romero LE, Villamar-Cruz O, Pacheco A, et al. A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells. Oncogene 2010;29:5839-49
64. Mott HR, Owen D, Nietlispach D, et al. Structure of the small G protein Cdc42 bound to the GTPase-binding domain of ACK. Nature 1999;399:384-8
65. Mahajan K, Mahajan NP. ACK1 tyrosine kinase: targeted inhibition to block cancer cell proliferation. Cancer Lett 2013;338:185-92
66. van der Horst EH, Degenhardt YY, Strelow A, et al. Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1. Proc Natl Acad Sci USA 2005;102:15901-6
67. Mahajan NP, Whang YE, Mohler JL, et al. Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. Cancer Res 2005;65:10514-23
68. Mahajan K, Coppola D, Rawal B, et al. Ack1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancer. J Biol Chem 2012;287:22112-22
69. Riedl SJ, Renatus M, Schwarzenbacher R, et al. Structural basis for the inhibition of caspase-3 by XIAP. Cell 2001;104:791-800
70. Chai J, Shiozaki E, Srinivasula SM, et al. Structural basis of caspase-7 inhibition by XIAP. Cell 2001;104:769-80
71. Srinivasula SM, Hegde R, Saleh A, et al. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 2001;410:112-16
72. Xu YC, Liu Q, Dai JQ, et al. Tissue microarray analysis of X-linked inhibitor of apoptosis (XIAP) expression in breast cancer patients. Med Oncol 2014;31:764
73. Huang Z. Bcl-2 family proteins as targets for anticancer drug design. Oncogene 2000;19:6627-31
74. Hassan M, Watari H, AbuAlmaaty A, et al. Apoptosis and molecular targeting therapy in cancer. Biomed Res Int 2014;2014:150845
75. Xiong S, Zheng Y, Jiang P, et al. MicroRNA-7 inhibits the growth of human non-small cell lung cancer A549 cells through targeting BCL-2. Int J Biol Sci 2011;7:805-14
76. Nicholson S, Whitehouse H, Naidoo K, et al. Yin Yang 1 in human cancer. Crit Rev Oncog 2011;16:245-60
77. Huerta-Yepez S, Vega M, Garban H, et al. Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis. Clin Immunol 2006;120:297-309
78. Zaravinos A, Spandidos DA. Yin yang 1 expression in human tumors. Cell Cycle 2010;9:512-22
79. Begon DY, Delacroix L, Vernimmen D, et al. Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells. J Biol Chem 2005;280:24428-34
80. Kashyap V, Bonavida B. Role of YY1 in the pathogenesis of prostate cancer and correlation with bioinformatic data sets of gene expression. Genes Cancer 2014;5:71-83
81. Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature 1999;401:297-300
82. Zack TI, Schumacher SE, Carter SL, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet 2013;45:1134-40
83. Zhang X, Hu S, Wang L, et al. MicroRNA-7 arrests cell cycle in G1 phase by directly targeting CCNE1 in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 2014;443:1078-84
84. Kanai K, Aramata S, Katakami S, et al. Proteasome activator PA28gamma stimulates degradation of GSK3-phosphorylated insulin transcription activator MAFA. J Mol Endocrinol 2011;47:119-27
85. Chen X, Barton LF, Chi Y, et al. Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome. Mol Cell 2007;26:843-52
86. Wan ZX, Yuan DM, Zhuo YM, et al. The proteasome activator PA28gamma, a negative regulator of p53, is transcriptionally up-regulated by p53. Int J Mol Sci 2014;15:2573-84
87. Wang X, Tu S, Tan J, et al. REG gamma: a potential marker in breast cancer and effect on cell cycle and proliferation of breast cancer cell. Med Oncol 2011;28:31-41
88. Okamura T, Taniguchi S, Ohkura T, et al. Abnormally high expression of proteasome activator-gamma in thyroid neoplasm. J Clin Endocrinol Metab 2003;88:1374-83
89. Roessler M, Rollinger W, Mantovani-Endl L, et al. Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol Cell Proteomics 2006;5:2092-101
90. Tian M, Xiaoyi W, Xiaotao L, et al. Proteasomes reactivator REG gamma enchances oncogenicity of MDA-MB-231 cell line via promoting cell proliferation and inhibiting apoptosis. Cell Mol Biol (Noisy-le-grand) 2009;55(Suppl):OL1121-31
91. Sanchez N, Gallagher M, Lao N, et al. MiR-7 triggers cell cycle arrest at the G1/S transition by targeting multiple genes including Skp2 and Psme3. PLoS One 2013;8:e65671
92. Kitano M, Rahbari R, Patterson EE, et al. Evaluation of candidate diagnostic microRNAs in thyroid fine-needle aspiration biopsy samples. Thyroid 2012;22:285-91
93. Wang S, Xiang J, Li Z, et al. A plasma microRNA panel for early detection of colorectal cancer. Int J Cancer 2015;136(1):152-61
94. Ahmed FE, Ahmed NC, Vos PW, et al. Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle. Cancer Genomics Proteomics 2013;10:93-113
95. Zhang Y, Wang Z, Gemeinhart RA. Progress in microRNA delivery. J Control Release 2013;172:962-74
96. Trang P, Wiggins JF, Daige CL, et al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 2011;19:1116-22
97. Baigude H, Rana TM. Interfering nanoparticles for silencing microRNAs. Methods Enzymol 2012;509:339-53
98. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013;12:847-65
99. Cho WC. MicroRNAs as therapeutic targets and their potential applications in cancer therapy. Expert Opin Ther Targets 2012;16:747-59
100. Liu R, Liu X, Zheng Y, et al. MicroRNA-7 sensitizes non-small cell lung cancer cells to paclitaxel. Oncol Lett 2014;8:2193-200
101. Pogribny IP, Filkowski JN, Tryndyak VP, et al. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 2010;127:1785-94
102. Tu CY, Chen CH, Hsia TC, et al. Trichostatin A suppresses EGFR expression through induction of microRNA-7 in an HDAC-independent manner in lapatinib-treated cells. Biomed Res Int 2014;2014:168949
103. Hsia TC, Tu CY, Chen YJ, et al. Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells. Mol Pharmacol 2013;83:857-69